LA SETA CATAMANCIO, SIMONA
LA SETA CATAMANCIO, SIMONA
Universita' degli Studi di MILANO
Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects
2002 S. Rusconi, E. Bulgheroni, S. La Seta-Catamancio, F.G. Croce, M. Lo Cicero, P.M. Citterio, M. Galli
Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine
2001 S. Rusconi, S. LA SETA CATAMANCIO, P. Citterio, E. Bulgheroni, S. Kurtagic, M. Galazzi, F.G. Croce, M. Moroni, M. Galli
In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure
2001 S. La Seta-Catamancio, M.P. De Pasquale, P. Citterio, S. Kurtagic, M. Galli, S. Rusconi
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215
2000 S. Rusconi, S. La Seta Catamancio, F. Sheridan, D. Parker
In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs
2000 S. Rusconi, D.P. Merrill, S. La Seta Catamancio, P. Citterio, E. Bulgheroni, F. Croce, T.C. Chou, O.O. Yang, S.H. Herrmann, M. Galli, M.S. Hirsch
In vitro inhibition of HIV-1 by Met-SDF-1β alone or in combination with antiretroviral drugs
2000 S. Rusconi, D.P. Merrill, S. La Seta Catamancio, P. Citterio, E. Bulgheroni, F. Croce, T.-. Chou, O.O. Yang, S.H. Herrmann, M. Galli, M.S. Hirsch
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors
2000 S. Rusconi, S. La Seta Catamancio, P. Citterio, S. Kurtagic, M. Violin, C. Balotta, M. Moroni, M. Galli, A. d'Arminio Monforte
Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection : in vitro studies of mixed virus infections
2000 S. Rusconi, S. La Seta Catamancio, P. Citterio, E. Bulgheroni, F. Croce, S.H. Herrmann, RE.O fford, M. Galli, M.S. Hirsch
Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase
2000 P. Bonfanti, I. Faggion, S. La Seta-Catamancio, M. Violin, C. Balotta, S. Rusconi
Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation
1999 S. Rusconi, S. La Seta-Catamancio, S. Kurtagic, M. Galazzi, D. Arienti, D. Trabattoni, J. Wilken, D. A. Thompson, R. E. Offord, M. Galli, M. Clerici
Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine
1999 L. Milazzo, S. Rusconi, L. Testa, S. La Seta-Catamancio, M. Galazzi, S. Kurtagic, P.M. Citterio, M. Gianotto, A. Grassini, F. Adorni, A. d'Arminio-Monforte, M. Galli, M. Moroni
Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES
1999 S. Rusconi, D. Merrill, S. La Seta-Catamancio, P.M. Citterio, R. Offord, M. Hirsch
Rapid onset of M184V mutation and phenotypic resistance to stavudine in zidovudine pre-treated HIV-1-infected individuals receiving the therapeutic regimens zidovudine plus lamivudine or stavudine plus lamivudine
1998 S. Rusconi, L. Milazzo, L. Testa, S. La Seta-Catamancio, M. Galazzi, S. Kurtagic, P. Citterio, M. Gianotto, F. Adorni, A. d'Arminio-Monforte, M. Galli, M. Moroni
Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure
1998 S. Rusconi, M. De Pasquale, L. Milazzo, S. Kurtagic, E. Bulgheroni, P.M. Citterio, M. Galazzi, S. La Seta-Catamancio, M. Galli